{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:02:00Z","timestamp":1789570920545,"version":"build-2803163510"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40266-026-01321-w","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:12:35Z","timestamp":1788768755000},"page":"791-815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of Ageing on the Pharmacology, Efficacy and Safety of Oral Targeted Therapies for Inflammatory Bowel Disease: Focus on Janus Kinase (JAK) Inhibitors and Sphingosine-1-Phosphate (S1P) Receptor Modulators"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6038-9295","authenticated-orcid":false,"given":"Luc J. J.","family":"Derijks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Karapinar-\u00c7arkit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatan","family":"Mujagi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob J.","family":"van Marum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J.","family":"Pierik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"21","key":"1321_CR1","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","volume":"361","author":"C Abraham","year":"2009","unstructured":"Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066\u201378.","journal-title":"N Engl J Med"},{"issue":"27","key":"1321_CR2","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383(27):2652\u201364.","journal-title":"N Engl J Med"},{"issue":"6","key":"1321_CR3","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","volume":"140","author":"J Cosnes","year":"2011","unstructured":"Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785\u201394.","journal-title":"Gastroenterology"},{"issue":"2","key":"1321_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf017","volume":"19","author":"RCA van Linschoten","year":"2025","unstructured":"van Linschoten RCA, van Leeuwen N, van Klaveren D, Pierik MJ, Creemers R, Hendrix EMB, et al. Prevalence, incidence, and mortality of inflammatory bowel disease in the Netherlands: development and external validation of machine learning models. J Crohns Colitis. 2025;19(2):jjaf017.","journal-title":"J Crohns Colitis"},{"key":"1321_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211023399","volume":"14","author":"SJ Hong","year":"2021","unstructured":"Hong SJ, Katz S. The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management. Ther Adv Gastroenterol. 2021;14:17562848211023399.","journal-title":"Ther Adv Gastroenterol"},{"issue":"5","key":"1321_CR6","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1016\/S2666-7568(22)00060-5","volume":"3","author":"S Vieujean","year":"2022","unstructured":"Vieujean S, Caron B, Jairath V, Benetos A, Danese S, Louis E, et al. Is it time to include older adults in inflammatory bowel disease trials? A call for action. Lancet Healthy Longev. 2022;3(5):e356\u201366.","journal-title":"Lancet Healthy Longev."},{"issue":"8","key":"1321_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-019-0705-6","volume":"21","author":"JW Windsor","year":"2019","unstructured":"Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep. 2019;21(8):40.","journal-title":"Curr Gastroenterol Rep"},{"issue":"3","key":"1321_CR8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/j.gastro.2017.10.034","volume":"154","author":"AH Everhov","year":"2018","unstructured":"Everhov AH, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, Soderling J, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology. 2018;154(3):518-28.e15.","journal-title":"Gastroenterology"},{"issue":"5","key":"1321_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/apt.14494","volume":"47","author":"M Manosa","year":"2018","unstructured":"Manosa M, Calafat M, de Francisco R, Garcia C, Casanova MJ, Huelin P, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. Aliment Pharmacol Ther. 2018;47(5):605\u201314.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1321_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020533","volume":"12","author":"A Fons","year":"2023","unstructured":"Fons A, Kalisvaart K, Maljaars J. Frailty and inflammatory bowel disease: a scoping review of current evidence. J Clin Med. 2023;12(2):533.","journal-title":"J Clin Med"},{"issue":"4","key":"1321_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15041440","volume":"15","author":"S Salvatori","year":"2026","unstructured":"Salvatori S, Marafini I, Monteleone G. Understanding frailty in IBD: implications for clinical outcomes and multidisciplinary care. J Clin Med. 2026;15(4):1440.","journal-title":"J Clin Med"},{"issue":"9","key":"1321_CR12","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/ibd\/izab052","volume":"27","author":"B Kochar","year":"2021","unstructured":"Kochar B, Kalasapudi L, Ufere NN, Nipp RD, Ananthakrishnan AN, Ritchie CS. Systematic review of inclusion and analysis of older adults in randomized controlled trials of medications used to treat inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27(9):1541\u20133.","journal-title":"Inflamm Bowel Dis"},{"issue":"10341","key":"1321_CR13","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113\u201328.","journal-title":"Lancet"},{"issue":"10292","key":"1321_CR14","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus JEV, Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372\u201384.","journal-title":"Lancet"},{"issue":"21","key":"1321_CR15","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Panes J, Lacerda AP, Peyrin-Biroulet L, D\u2019Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388(21):1966\u201380.","journal-title":"N Engl J Med"},{"issue":"14","key":"1321_CR16","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D\u2019Haens G, Wolf DC, Jovanovic I, Hanauer SB, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280\u201391.","journal-title":"N Engl J Med"},{"issue":"18","key":"1321_CR17","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723\u201336.","journal-title":"N Engl J Med"},{"issue":"10383","key":"1321_CR18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159\u201371.","journal-title":"Lancet"},{"issue":"4","key":"1321_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/ibd\/izaf273","volume":"32","author":"JP Gisbert","year":"2026","unstructured":"Gisbert JP, Chaparro M. Janus kinase inhibitors for inflammatory bowel disease: concise questions and answers on their use in clinical practice. Inflamm Bowel Dis. 2026;32(4):775\u2013802.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"1321_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.cgh.2025.07.028","volume":"24","author":"R Panaccione","year":"2026","unstructured":"Panaccione R, Regueiro M, Lee SD, Atreya R, Pedersen G, Broide E, et al. Upadacitinib maintenance therapy in Crohn\u2019s disease: final results from the randomized phase 3 U-ENDURE study. Clin Gastroenterol Hepatol. 2026;24(3):772\u201383.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"1321_CR21","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S2468-1253(23)00208-X","volume":"8","author":"S Vermeire","year":"2023","unstructured":"Vermeire S, Danese S, Zhou W, Ilo D, Klaff J, Levy G, et al. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study. Lancet Gastroenterol Hepatol. 2023;8(11):976\u201389.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"1321_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/acr.25282","volume":"76","author":"N Singh","year":"2024","unstructured":"Singh N, Gold LS, Lee J, Wysham KD, Andrews JS, Makris UE, et al. Frailty and risk of serious infections in patients with rheumatoid arthritis treated with biologic or targeted-synthetic disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 2024;76(5):627\u201335.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1321_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106157","volume":"92","author":"N Al Worikat","year":"2024","unstructured":"Al Worikat N, Molaei F, Zanotto A, Tabatabaei A, Lynch SG, Troen BR, et al. Frailty in multiple sclerosis: a scoping review. Mult Scler Relat Disord. 2024;92:106157.","journal-title":"Mult Scler Relat Disord."},{"issue":"5","key":"1321_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001","volume":"14","author":"AM Shawky","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14(5):1001.","journal-title":"Pharmaceutics"},{"issue":"16","key":"1321_CR25","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.3390\/jcm13164678","volume":"13","author":"A Strigac","year":"2024","unstructured":"Strigac A, Caban M, Malecka-Wojciesko E, Talar-Wojnarowska R. Safety and effectiveness of thiopurines and small molecules in elderly patients with inflammatory bowel diseases. J Clin Med. 2024;13(16):4678.","journal-title":"J Clin Med"},{"issue":"4","key":"1321_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","volume":"83","author":"P Nunez","year":"2023","unstructured":"Nunez P, Quera R, Yarur AJ. Safety of Janus kinase inhibitors in inflammatory bowel diseases. Drugs. 2023;83(4):299\u2013314.","journal-title":"Drugs"},{"issue":"12","key":"1321_CR27","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023\u201338.","journal-title":"J Med Chem"},{"issue":"23","key":"1321_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235660","volume":"10","author":"P Dudek","year":"2021","unstructured":"Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, safety and future perspectives of JAK inhibitors in the IBD treatment. J Clin Med. 2021;10(23):5660.","journal-title":"J Clin Med"},{"issue":"4","key":"1321_CR29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"1321_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2455536","volume":"57","author":"H Yang","year":"2025","unstructured":"Yang H, An T, Zhao Y, Shi X, Wang B, Zhang Q. Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis. Ann Med. 2025;57(1):2455536.","journal-title":"Ann Med"},{"key":"1321_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells12131722","author":"W Fries","year":"2023","unstructured":"Fries W, Basile G, Bellone F, Costantino G, Viola A. Efficacy and safety of biological therapies and JAK inhibitors in older patients with inflammatory bowel disease. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12131722.","journal-title":"Cells"},{"issue":"17","key":"1321_CR32","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.3748\/wjg.v20.i17.4857","volume":"20","author":"F Magro","year":"2014","unstructured":"Magro F, Soares JB, Fernandes D. Venous thrombosis and prothrombotic factors in inflammatory bowel disease. World J Gastroenterol. 2014;20(17):4857\u201372.","journal-title":"World J Gastroenterol"},{"key":"1321_CR33","unstructured":"EMA. Tofacitinib (Xeljanz\u00ae) summary of product characteristics. 2017. https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h135037_smpc.pdf. p. 1\u2013187."},{"issue":"9","key":"1321_CR34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/17474124.2020.1785868","volume":"14","author":"D Gilardi","year":"2020","unstructured":"Gilardi D, Gabbiadini R, Allocca M, Correale C, Fiorino G, Furfaro F, et al. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Rev Gastroenterol Hepatol. 2020;14(9):797\u2013806.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"9","key":"1321_CR35","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","volume":"12","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2014;12(9):1485-93.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1321_CR36","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","volume":"66","author":"J Panes","year":"2017","unstructured":"Panes J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D\u2019Haens G, et al. Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66(6):1049\u201359.","journal-title":"Gut"},{"issue":"1","key":"1321_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ibd\/izac084","volume":"29","author":"GR Lichtenstein","year":"2023","unstructured":"Lichtenstein GR, Bressler B, Francisconi C, Vermeire S, Lawendy N, Salese L, et al. Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2023;29(1):27\u201341.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"1321_CR38","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.14309\/ajg.0000000000002761","volume":"119","author":"N Khan","year":"2024","unstructured":"Khan N, Sundararajan R, Patel M, Trivedi C, Yang YX. Effectiveness of tofacitinib in patients with ulcerative colitis: a nationwide Veterans Administration cohort study. Am J Gastroenterol. 2024;119(8):1632\u20135.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"1321_CR39","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","volume":"14","author":"S Honap","year":"2020","unstructured":"Honap S, Chee D, Chapman TP, Patel M, Kent AJ, Ray S, et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis. 2020;14(10):1385\u201393.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"1321_CR40","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/ibd\/izad242","volume":"30","author":"RS Dalal","year":"2024","unstructured":"Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JR. Clinical and endoscopic outcomes through 78 weeks of tofacitinib therapy for ulcerative colitis in a US cohort. Inflamm Bowel Dis. 2024;30(10):1707\u201313.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"1321_CR41","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/ecco-jcc\/jjad158","volume":"18","author":"A Viola","year":"2024","unstructured":"Viola A, Li Voti R, Bivacqua C, De Francesco C, Muscianisi M, Costantino G, et al. Mitigating the risk of tofacitinib-induced adverse events in the elderly population with ulcerative colitis. J Crohns Colitis. 2024;18(3):488\u201391.","journal-title":"J Crohns Colitis"},{"issue":"11","key":"1321_CR42","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.cgh.2025.01.036","volume":"23","author":"A Singh","year":"2025","unstructured":"Singh A, Bhardwaj A, Sharma R, Jain D, Midha V, Sood A. Effectiveness and safety of tofacitinib in biologic-naive elderly patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2025;23(11):2045-7.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1321_CR43","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cgh.2020.10.004","volume":"20","author":"JF Colombel","year":"2022","unstructured":"Colombel JF, Osterman MT, Thorpe AJ, Salese L, Nduaka CI, Zhang H, et al. Maintenance of remission with tofacitinib therapy in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20(1):116-25.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"1321_CR44","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cgh.2010.03.022","volume":"8","author":"CY Ha","year":"2010","unstructured":"Ha CY, Newberry RD, Stone CD, Ciorba MA. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol. 2010;8(8):682-7.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1321_CR45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","volume":"143","author":"MD Long","year":"2012","unstructured":"Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(2):390-9.e1.","journal-title":"Gastroenterology"},{"issue":"12","key":"1321_CR46","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","volume":"4","author":"G Gupta","year":"2006","unstructured":"Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(12):1483\u201390.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1321_CR47","unstructured":"US FDA. Janus kinase (JAK) inhibitors: drug safety communication. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death. 2021. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk. Accessed 10 Feb 2026."},{"key":"1321_CR48","unstructured":"EMA. Upadacitinib (Rinvoq\u00ae) summary of product characteristics. 2019. https:\/\/www.ema.europa.eu\/nl\/documents\/product-information\/rinvoq-epar-product-information_nl.pdf. p. 1\u2013107."},{"issue":"1","key":"1321_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","volume":"17","author":"MF Mohamed","year":"2024","unstructured":"Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1):e13688.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"1321_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","volume":"59","author":"MF Mohamed","year":"2020","unstructured":"Mohamed MF, Klunder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2020;59(5):531\u201344.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1321_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf198","volume":"20","author":"S Vermeire","year":"2026","unstructured":"Vermeire S, Colombel JF, Danese S, Panaccione R, Peyrin-Biroulet L, Beck K, et al. Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b\/3 studies in patients with moderately to severely active ulcerative colitis or Crohn\u2019s disease. J Crohns Colitis. 2026;20(1):jjaf198.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"1321_CR52","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1007\/s10620-025-09647-y","volume":"71","author":"NM Garcia","year":"2026","unstructured":"Garcia NM, Memel Z, Zou Y, Thiemann A, Dort C, Beck K. Upadacitinib is safe and effective in older adults: a real-world experience comparing safety and efficacy in younger versus older adults with inflammatory bowel disease. Dig Dis Sci. 2026;71(6):2365\u201373.","journal-title":"Dig Dis Sci"},{"key":"1321_CR53","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.14309\/01.ajg.0000995852.39535.01","volume":"118","author":"N Chowla","year":"2023","unstructured":"Chowla N, Tariq R, Loftus E. S29 safety of upadacitinib in older patients with ulcerative colitis: a real-world experience. Am J Gastroenterol. 2023;118:S8-9.","journal-title":"Am J Gastroenterol"},{"key":"1321_CR54","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/ibd\/izac247.155","volume":"29","author":"J Levine","year":"2023","unstructured":"Levine J, McKibbin J, Ham R, Higgins P, Bishu S, Berinstein J. Use of upadactinib in 11 tofacitinib-refractory ulcerative colitis patients at a single tertiary care center. Inflamm Bowel Dis. 2023;29:S81.","journal-title":"Inflamm Bowel Dis"},{"key":"1321_CR55","unstructured":"EMA. Filgotinib (Jyseleca\u00ae) summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/nl\/documents\/product-information\/jyseleca-epar-product-information_nl.pdf. p. 1\u201349."},{"issue":"6","key":"1321_CR56","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","volume":"61","author":"F Namour","year":"2022","unstructured":"Namour F, Anderson K, Nelson C, Tasset C. Filgotinib: a clinical pharmacology review. Clin Pharmacokinet. 2022;61(6):819\u201332.","journal-title":"Clin Pharmacokinet"},{"issue":"18","key":"1321_CR57","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-020-01439-0","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S, Keam SJ. Filgotinib: first approval. Drugs. 2020;80(18):1987\u201397.","journal-title":"Drugs"},{"issue":"2","key":"1321_CR58","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S2468-1253(24)00272-3","volume":"10","author":"S Vermeire","year":"2025","unstructured":"Vermeire S, Schreiber S, Rubin DT, D\u2019Haens G, Reinisch W, Watanabe M, et al. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn\u2019s disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025;10(2):138\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1321_CR59","doi-asserted-by":"publisher","first-page":"i085","DOI":"10.1093\/ecco-jcc\/jjab232.076","volume":"16","author":"S Schreiber","year":"2022","unstructured":"Schreiber S, Loftus EV, Maaser C, Danese S, Rudolph C, Jongen R, et al. Efficacy and safety of filgotinib in patients with ulcerative colitis stratified by age: post hoc analysis of the phase 2b\/3 SELECTION and SELECTIONLTE studies. J Crohns Colitis. 2022;16:i085-i87.","journal-title":"J Crohns Colitis"},{"key":"1321_CR60","doi-asserted-by":"crossref","unstructured":"Young D, Rahmany S, Taylor D, Davis E, Colwill M, Kalyanji Mehta S, et al. Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres. Drugs Context. 2025;14:2404-11-1.","DOI":"10.7573\/dic.2024-11-1"},{"issue":"11","key":"1321_CR61","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/apt.17961","volume":"59","author":"S Akiyama","year":"2024","unstructured":"Akiyama S, Yokoyama K, Yagi S, Shinzaki S, Tsuruta K, Yoshioka S, et al. Efficacy and safety of filgotinib for ulcerative colitis: a real-world multicenter retrospective study in Japan. Aliment Pharmacol Ther. 2024;59(11):1413\u201324.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1321_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.70141","volume":"14","author":"MR Naber","year":"2026","unstructured":"Naber MR, van der Meulen AE, Voorneveld PW, Veltkamp SHC, van Bodegraven AA, Bodelier A, et al. Filgotinib is an effective and safe treatment option for difficult-to-treat ulcerative colitis: real-world evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry. United Eur Gastroenterol J. 2026;14(1):e70141.","journal-title":"United Eur Gastroenterol J"},{"issue":"10","key":"1321_CR63","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s40265-024-02094-5","volume":"84","author":"K Kitsou","year":"2024","unstructured":"Kitsou K, Kokkotis G, Rivera-Nieves J, Bamias G. Targeting the sphingosine-1-phosphate pathway: new opportunities in inflammatory bowel disease management. Drugs. 2024;84(10):1179\u201397.","journal-title":"Drugs"},{"issue":"4","key":"1321_CR64","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","volume":"20","author":"M Argollo","year":"2020","unstructured":"Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, et al. Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther. 2020;20(4):413\u201320.","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"1321_CR65","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/17425255.2016.1196188","volume":"12","author":"PE Juif","year":"2016","unstructured":"Juif PE, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. Expert Opin Drug Metab Toxicol. 2016;12(8):879\u201395.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1321_CR66","unstructured":"EMA. Ozanimod (Zeposia\u00ae) summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/nl\/documents\/product-information\/zeposia-epar-productinformation_nl.pdf.. p. 1\u201354."},{"key":"1321_CR67","unstructured":"EMA. Etrasimod (Velsipity\u00ae) summary of product characteristics. 2024. https:\/\/www.geneesmiddeleninformatiebank.nl\/ords\/f?p=111:3::SEARCH:::P0_DOMAIN P0_LANG,P3_RVG1:H,NL,130781. p. 1\u201348."},{"issue":"9","key":"1321_CR68","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/17425255.2024.2402931","volume":"20","author":"S Vieujean","year":"2024","unstructured":"Vieujean S, Peyrin-Biroulet L. Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis. Expert Opin Drug Metab Toxicol. 2024;20(9):881\u201392.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"1321_CR69","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/ecco-jcc\/jjad112","volume":"17","author":"BE Sands","year":"2023","unstructured":"Sands BE, Schreiber S, Blumenstein I, Chiorean MV, Ungaro RC, Rubin DT. Clinician\u2019s guide to using ozanimod for the treatment of ulcerative colitis. J Crohns Colitis. 2023;17(12):2012\u201325.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"1321_CR70","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","volume":"18","author":"S Danese","year":"2024","unstructured":"Danese S, Panaccione R, Abreu MT, Rubin DT, Ghosh S, Dignass A, et al. Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension. J Crohns Colitis. 2024;18(2):264\u201374.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"1321_CR71","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","volume":"5","author":"BG Feagan","year":"2020","unstructured":"Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, et al. Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020;5(9):819\u201328.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1321_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106958","volume":"122","author":"BG Feagan","year":"2022","unstructured":"Feagan BG, Schreiber S, Afzali A, Rieder F, Hyams J, Kollengode K, et al. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn\u2019s disease: the YELLOWSTONE clinical trial program. Contemp Clin Trials. 2022;122:106958.","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"1321_CR73","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ibd\/izaf258","volume":"32","author":"AS Faye","year":"2026","unstructured":"Faye AS, Rubin DT, Siegel CA, Long MD, Khan N, Danese S, et al. Safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis stratified by age. Inflamm Bowel Dis. 2026;32(3):512\u201325.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"1321_CR74","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10620-023-08178-8","volume":"69","author":"NA Cohen","year":"2024","unstructured":"Cohen NA, Choi D, Garcia N, Choi NK, Picker E, Krugliak Cleveland N, et al. Real world clinical effectiveness and safety of ozanimod in the treatment of ulcerative colitis: 1-year follow-up from a tertiary center. Dig Dis Sci. 2024;69(2):579\u201387.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"1321_CR75","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/ibd\/izaf319","volume":"32","author":"DT Rubin","year":"2026","unstructured":"Rubin DT, Danese S, Nakase H, Ungaro RC, Wolf DC, Alekseeva O, et al. Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis. Inflamm Bowel Dis. 2026;32(5):954\u201362.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1321_CR76","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","volume":"15","author":"S Vermeire","year":"2021","unstructured":"Vermeire S, Chiorean M, Panes J, Peyrin-Biroulet L, Zhang J, Sands BE, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J Crohns Colitis. 2021;15(6):950\u20139.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"1321_CR77","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1093\/ibd\/izae308","volume":"31","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Allegretti JR, Loftus EV Jr, Irving PM, Banerjee R, Charabaty A, et al. Assessment and impact of age on the safety and efficacy of etrasimod in patients with ulcerative colitis: a post hoc analysis of data from the ELEVATE UC clinical program. Inflamm Bowel Dis. 2025;31(9):2352\u201362.","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl. 1","key":"1321_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf231.983","volume":"20","author":"E Vayreda","year":"2026","unstructured":"Vayreda E, Vasconcellos P, Reis S, Matini L, Punj Sharda A, Dunbar G, et al. P0802 etrasimod real-world experience in ulcerative colitis: a multicentre cohort study. J Crohns Colitis. 2026;20(Suppl. 1):jjaf231.983.","journal-title":"J Crohns Colitis"},{"key":"1321_CR79","doi-asserted-by":"publisher","first-page":"i1537","DOI":"10.1093\/ecco-jcc\/jjae190.0975","volume":"19","author":"J St-Pierre","year":"2025","unstructured":"St-Pierre J, Choi D, Yanofsky R, Fear E, Rubin DT. P0801 Real-world effectiveness and tolerability of etrasimod in active ulcerative colitis: a 26-week observational study. J Crohns Colitis. 2025;19:i1537.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"1321_CR80","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1093\/ecco-jcc\/jjae060","volume":"18","author":"M Regueiro","year":"2024","unstructured":"Regueiro M, Siegmund B, Yarur AJ, Steinwurz F, Gecse KB, Goetsch M, et al. Etrasimod for the treatment of ulcerative colitis: analysis of infection events from the ELEVATE UC clinical programme. J Crohns Colitis. 2024;18(10):1596\u2013605.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1321_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2024-001516","volume":"12","author":"S Vermeire","year":"2025","unstructured":"Vermeire S, Rubin DT, Peyrin-Biroulet L, Dubinsky MC, Regueiro M, Irving PM, et al. Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025;12(1):e001516.","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"1321_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-19679-z","volume":"15","author":"Q Guo","year":"2025","unstructured":"Guo Q, Shan M, Gao W. Safety evaluation of etrasimod for ulcerative colitis based on the FAERS database. Sci Rep. 2025;15(1):36558.","journal-title":"Sci Rep"},{"issue":"8","key":"1321_CR83","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.dld.2022.12.024","volume":"55","author":"P Sousa","year":"2023","unstructured":"Sousa P, Bertani L, Rodrigues C. Management of inflammatory bowel disease in the elderly: a review. Dig Liver Dis. 2023;55(8):1001\u20139.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"1321_CR84","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/ecco-jcc\/jjad175","volume":"18","author":"VER Asscher","year":"2024","unstructured":"Asscher VER, Rodriguez Girondo M, Fens J, Waars SN, Stuyt RJL, Baven-Pronk AMC, et al. Frailty screening is associated with hospitalization and decline in quality of life and functional status in older patients with inflammatory bowel disease. J Crohns Colitis. 2024;18(4):516\u201324.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"1321_CR85","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.cgh.2022.01.001","volume":"20","author":"B Kochar","year":"2022","unstructured":"Kochar B, Jylhava J, Soderling J, Ritchie CS, Group SS, Ludvigsson JF, et al. Prevalence and implications of frailty in older adults with incident inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2022;20(10):2358-65 e11.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1321_CR86","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6\u201314.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1321_CR87","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s40495-025-00425-y","volume":"11","author":"A Ruiz","year":"2025","unstructured":"Ruiz A, DiCristina S. Absorption to excretion: the aging body\u2019s take on drugs: a review of pharmacokinetic changes and their impact on medication management. Curr Pharmacol Rep. 2025;11(1):42.","journal-title":"Curr Pharmacol Rep."},{"issue":"4","key":"1321_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12040775","volume":"12","author":"E Quiros-Roldan","year":"2024","unstructured":"Quiros-Roldan E, Sottini A, Natali PG, Imberti L. The impact of immune system aging on infectious diseases. Microorganisms. 2024;12(4):775.","journal-title":"Microorganisms"},{"issue":"1","key":"1321_CR89","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ibd\/izac063","volume":"29","author":"KL Winthrop","year":"2023","unstructured":"Winthrop KL, Vermeire S, Long MD, Panes J, Ng SC, Kulisek N, et al. Long-term risk of herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2023;29(1):85\u201396.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"1321_CR90","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"issue":"30","key":"1321_CR91","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.3748\/wjg.v25.i30.4158","volume":"25","author":"JF LeBlanc","year":"2019","unstructured":"LeBlanc JF, Wiseman D, Lakatos PL, Bessissow T. Elderly patients with inflammatory bowel disease: updated review of the therapeutic landscape. World J Gastroenterol. 2019;25(30):4158\u201371.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1321_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-020-01801-7","volume":"20","author":"S Church","year":"2020","unstructured":"Church S, Rogers E, Rockwood K, Theou O. A scoping review of the Clinical Frailty Scale. BMC Geriatr. 2020;20(1):393.","journal-title":"BMC Geriatr"},{"issue":"4","key":"1321_CR93","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/jcsm.13260","volume":"14","author":"M Okamura","year":"2023","unstructured":"Okamura M, Konishi M, Butler J, Kalantar-Zadeh K, von Haehling S, Anker SD. Kidney function in cachexia and sarcopenia: facts and numbers. J Cachexia Sarcopenia Muscle. 2023;14(4):1589\u201395.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1321_CR94","unstructured":"EMA. Reflection paper on physical frailty: instruments for baseline characterisation of older populations in clinical trials. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-physical-frailty-instruments-baseline-characterisation-older-populations-clinical-trials-first-version_en.pdf p. 1\u201322."},{"issue":"5","key":"1321_CR95","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ueg2.12559","volume":"12","author":"S Harnik","year":"2024","unstructured":"Harnik S, Ungar B, Loebstein R, Ben-Horin S. A gastroenterologist\u2019s guide to drug interactions of small molecules for inflammatory bowel disease. United Eur Gastroenterol J. 2024;12(5):627\u201337.","journal-title":"United Eur Gastroenterol J"},{"issue":"5","key":"1321_CR96","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/ueg2.12750","volume":"13","author":"N Grellier","year":"2025","unstructured":"Grellier N, Kirchgesner J. Drug interaction with advanced therapies in inflammatory bowel diseases: a blind spot to tackle. United Eur Gastroenterol J. 2025;13(5):663\u20134.","journal-title":"United Eur Gastroenterol J"},{"issue":"5","key":"1321_CR97","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2020.03.017","volume":"145","author":"CE Gustafson","year":"2020","unstructured":"Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine responses. J Allergy Clin Immunol. 2020;145(5):1309\u201321.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1321_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00874-4","volume":"9","author":"Y Hou","year":"2024","unstructured":"Hou Y, Chen M, Bian Y, Hu Y, Chuan J, Zhong L, et al. Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies. NPJ Vaccines. 2024;9(1):77.","journal-title":"NPJ Vaccines"},{"issue":"1","key":"1321_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00757-0","volume":"8","author":"D Curran","year":"2023","unstructured":"Curran D, Doherty TM, Lecrenier N, Breuer T. Healthy ageing: herpes zoster infection and the role of zoster vaccination. NPJ Vaccines. 2023;8(1):184.","journal-title":"NPJ Vaccines"},{"issue":"1","key":"1321_CR100","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.vaccine.2022.10.063","volume":"41","author":"KM Sullivan","year":"2023","unstructured":"Sullivan KM, Farraye FA, Winthrop KL, Willer DO, Vink P, Tavares-Da-Silva F. Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions. Vaccine. 2023;41(1):36\u201348.","journal-title":"Vaccine"},{"issue":"9","key":"1321_CR101","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/apt.17674","volume":"58","author":"S Schreiber","year":"2023","unstructured":"Schreiber S, Rogler G, Watanabe M, Vermeire S, Maaser C, Danese S, et al. Integrated safety analysis of filgotinib for ulcerative colitis: results from SELECTION and SELECTION LTE. Aliment Pharmacol Ther. 2023;58(9):874\u201387.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01321-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01321-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01321-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:01:55Z","timestamp":1789567315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01321-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":101,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1321"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01321-w","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luc J.J. Derijks has served as a speaker for AbbVie, Celltrion, Janssen-Cilag and Takeda and has developed continuing education materials for Ferring, all outside the submitted work. Fatma Karapinar-\u00c7arkit has\u00a0no conflicts of interest that are directly relevant to the content of this article. Zlatan Mujagi\u0107 received grants from ZonMw, Niels Stensen Fellowship, MLDS, Top consortium for Knowledge and Innovation (TKI) and Galapagos; advisory board fees from Johnson & Johnson, Eli Lilly and Pfizer (paid to host institution)l and speaker\u2019s fees from Friso-Friesland Campina, Galapagos, Eli Lilly and Takeda (paid to host institution), all outside the submitted work. Rob J. van Marum has no conflicts of interest that are directly relevant to the content of this article. Marieke J. Pierik has received grants from Falk Pharma, the European Commission, ZonMw, Takeda, Johnson & Johnson and AbbVie and non-financial support from Falk Pharma, Takeda, Johnson & Johnson, AbbVie, Ferring, Immunodiagnostics and MSD, all outside the submitted work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LD accepted the invitation and wrote the manuscript. All authors contributed to the drafting and critical revision of the manuscript and approved the final version of this manuscript.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}